The coronavirus exposed the US' reliance on India for generic drugs. But that supply chain is ultimately controlled by China
In this article for CNN, Priyali Sur examines the impact of COVID-19 on medicine supply and production in India and China, teasing apart how medicine supply chains between those countries interconnect.
The article examines the ways in which COVID-19 has affected India's production of medicines by interrupting supply of active pharmaceutical ingredients (APIs) from China. The author looks at India's role as a major producer of generic medicines sold around the world, and at its reliance on China, exploring how a disruption to supply and production in China could impact people's ability to access medicines they need. Jayasree K. Iyer is quoted in the article regarding concerns that pharmaceutical companies may not have sufficient stocks to meet their commitments.